E
Eckart Laack
Researcher at Eppendorf (Germany)
Publications - 28
Citations - 1195
Eckart Laack is an academic researcher from Eppendorf (Germany). The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 14, co-authored 28 publications receiving 1104 citations.
Papers
More filters
Journal ArticleDOI
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Mike Thomas,Jean-Louis Pujol,Paolo Bidoli,Olivier Molinier,Tarini Prasad Sahoo,Eckart Laack,Martin Reck,Jesus Corral,Symantha Melemed,William J. John,Nadia Chouaki,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +16 more
TL;DR: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexing-cisplatin induction therapy.
Journal ArticleDOI
Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer
Eckart Laack,A. Köhler,C. Kugler,T. Dierlamm,C. Knuffmann,G. Vohwinkel,A. Niestroy,N. Dahlmann,A. Peters,J. Berger,Walter Fiedler,D.K. Hossfeld +11 more
TL;DR: The hypothesis that the pretreatment serum level of MMP-9 is a new powerful prognostic marker and can help to stratify NSCLC patients with stage I/II disease into low- and high-risk groups is supported.
Journal ArticleDOI
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Claus-Peter Schneider,David F. Heigener,Kathrin Schott-von-Römer,Sylvia Gütz,Eckart Laack,Werner Digel,Wolf-Rüdiger Guschall,Andreas Franke,Heinrich Bodenstein,Claudia Schmidtgen,Martin Reck +10 more
TL;DR: The presence of EGFR mutations and EGFR FISH-positive tumors may predispose patients to achieving better outcomes on erlotinib, but may have a beneficial impact on prognosis (irrespective of treatment).
Journal ArticleDOI
Lectin Histochemistry of Resected Adenocarcinoma of the Lung : Helix pomatia Agglutinin Binding Is an Independent Prognostic Factor
Eckart Laack,Haleh Nikbakht,Anja Peters,Christian Kugler,Yvonne Jasiewicz,Lutz Edler,Dieter K. Hossfeld,Udo Schumacher +7 more
TL;DR: HPA binding was the primary marker-based predictor of prognosis in the patient population and allows to stratify patients with adenocarcinomas of the lung into a low- and a high-risk group.
Journal ArticleDOI
PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Michael Thomas,Jean-Louis Pujol,Paolo Bidoli,Oliver Molinier,Tarini Prasad Sahoo,Eckart Laack,Martin Reck,Jesus Corral Jaime,Symantha Melemed,William J. John,Nadia Chouaki,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +16 more
TL;DR: The PARAMOUNT trial showed that pem continuation maintenance therapy significantly reduced the risk of disease progression over plb (HR=0.62; 95% CI: 0.49-0.79; p <0.0001) in patients (pts) with advanced NS NSCLC who had not progressed during pem-cis induction as mentioned in this paper.